Under the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Not for submission under 37 CFR 1.99)

Application Number		09781162	
Filing Date		2001-02-13	
First Named Inventor	KAZU	JMA SATO	
Art Unit		3625	
Examiner Name	A. Shah		
Attorney Docket Number		00862.022116.	

			U.S.PATENTS				Remove			
Examiner Initial*	Cite No	Patent Number	r Kind Code ¹ Issue Date Name of Patentee or As			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	ind Publication Date Name of Patentee or Application of cited Document			Releva	s,Columns,Lines wh ant Passages or Re es Appear		
	1									
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	please click the Ad	d buttor		
				FOREI	GN PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lir where Relevant Passages or Relev Figures Appear	Ts
	1	11-015335	JP			1999-01-22	Atsumi			
	2	03-248166	JP			1991-11-06	Suzuki			
	3	10-333769	JP			1998-12-18	Iwama			

1991-07-12 Mitsui

	5	11-103291	JP		2006-10-04	Haneda				
	6	09-244760	JP		1997-09-19	Yoshihara				
	7	63-197966	JP		1988-08-16	Akita				
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Cite Initials* Cite No. (Control of the Author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and of country where published.										
1										
If you wish to add additional non-natural literature document citation information places aliak the Add button Add										

See Kind Codes of USPTO Patient Documents at www.lispTio.go/; or MPEP 901 04. ** Enter office that issued the document, by the law-lefter code (WPO Standard ST 3). ** For Japanese patient documents, the includes of the year of the surgor of the Emporor must precede the serial number of the patient document. ** White of document is the patients preceded as included to the location and with VPO dataset ST 1.6 (position \$2.5) patients in Spatiants to patient and extend and extend the ST and Standard ST 1.6 (position \$2.5) patients with spatients in Spatiants to patients. ** Applicants to patients and extend and extend standard ST 1.6 (position \$2.5) patients and extend and extend standard standard

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner Signature

03-162057

JF

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09781162		
Filing Date		2001-02-13		
First Named Inventor	KAZU	JMA SATO		
Art Unit		3625		
Examiner Name	A. Sh	ah		
Attorney Docket Number		00862.022116.		

42 746

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of forms foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any inclinication designated in 37 CPR1 156(c) more than three months prior to the filing of the information disclosure any inclinication.

- ☐ See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Edward A Kmett

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.			
Signature	/Edward Kmett/	Date (YYYY-MM-DD)	2006-10-05

Registration Number

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 3 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Comments of C

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information is used to the patient of t

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing impaction of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was fled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to published application, an application pare to published application and application and applications or an insurance of the published application and applications.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.